These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22271475)

  • 1. Design issues in randomized phase II/III trials.
    Korn EL; Freidlin B; Abrams JS; Halabi S
    J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seamlessly expanding a randomized phase II trial to phase III.
    Inoue LY; Thall PF; Berry DA
    Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design issues of randomized phase II trials and a proposal for phase II screening trials.
    Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
    J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inclusion of real world evidence in clinical development planning.
    Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
    Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated phase II/III clinical trials in oncology: a case study.
    Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
    Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trials: a long-term investment with promising returns.
    Sharma MR; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents.
    Rustomjee R; McClain B; Brennan MJ; McLeod R; Chetty-Makkan CM; McShane H; Hanekom W; Steel G; Mahomed H; Ginsberg AM; Shea J; Lockhart S; Self S; Churchyard GJ
    Tuberculosis (Edinb); 2013 Mar; 93(2):136-42. PubMed ID: 23266259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size tables for exact single-stage phase II designs.
    A'Hern RP
    Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
    Chen CM; Chi Y; Chang HM
    J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
    Sato A; Shimura M; Gosho M
    J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.
    Elsäßer A; Regnstrom J; Vetter T; Koenig F; Hemmings RJ; Greco M; Papaluca-Amati M; Posch M
    Trials; 2014 Oct; 15():383. PubMed ID: 25278265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethics and practice: alternative designs for phase III randomized clinical trials.
    Palmer CR; Rosenberger WF
    Control Clin Trials; 1999 Apr; 20(2):172-86. PubMed ID: 10227416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.